6-aminoisoquinoline compounds
6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
1. A compound, wherein the compound is a pharmaceutically acceptable salt of Formula IV:
wherein,
A is a substituted or unsubstituted chain containing from one to four member atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur, wherein the chain may be mono- or di-substituted with halogen, cyano, nitro, or C 1 -C 4 alkyl, or the substituted atoms may attach back to the main chain to form a ring;
R 1 and R 2 are, independently, hydrogen, hydroxyl, halogen, or cyano; and
R 3 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, amino, cyano, cycloalkyl, heterocycloalkyl, aryl, C 1 -C 4 alkyl aryl, heteroaryl, C 1 -C 4 alkyl heteroaryl, carbonyl, carbonylamino, thioalkyl, sulfonyl, sulfonylamino, acyl, or carboxyl.
2. The compound of claim 1 , wherein R 1 and R 2 are hydrogen.
3. The compound of claim 1 , wherein A is methylene or ethylene.
4. The compound of claim 1 , wherein A is —O—CH 2 — or —NH—CH 2 —.
5. The compound of claim 1 , wherein R 3 is alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, C 1 -C 4 alkyl aryl, heteroaryl, C 1 -C 4 alkyl heteroaryl, carbonyl, or carbonylamino.
6. The compound of claim 1 , wherein R 3 is aryl.
7. The compound of claim 6 , wherein R 3 is substituted with heteroaryl, acyl, carboxyl, carbonylamino, nitro, amino, cyano, halogen, alkoxy, or hydroxyl.
8. The compound of claim 6 , wherein R 3 is phenyl.
9. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of:
10. A pharmaceutical composition comprising:
a) the compound of claim 1 ; and
b) a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10 , wherein the carrier is a systemic or topical carrier.
12. The pharmaceutical composition of claim 11 , wherein the composition comprises about 0.001% to 10% of the compound and 90% to 99.999% of the systemic carrier.
13. A method of treating an eye disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound, wherein the compound is a pharmaceutically acceptable salt of Formula IV:
wherein,
A is a substituted or unsubstituted chain containing from one to four member atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur, wherein the chain may be mono- or di-substituted with halogen, cyano, nitro, or C 1 -C 4 alkyl, or the substituted atoms may attach back to the main chain to form a ring;
R 1 and R 2 are, independently, hydrogen, hydroxyl, halogen, or cyano; and
R 3 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, amino, cyano, cycloalkyl, heterocycloalkyl, aryl, C 1 -C 4 alkyl aryl, heteroaryl, C 1 -C 4 alkyl heteroaryl, carbonyl, carbonylamino, thioalkyl, sulfonyl, sulfonylamino, acyl, or carboxyl.
14. The method of claim 13 , wherein R 1 and R 2 are hydrogen.
15. The method of claim 13 , wherein A is methylene or ethylene.
16. The method of claim 13 , wherein A is —O—CH 2 — or —NH—CH 2 —.
17. The method of claim 13 , wherein R 3 is alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, C 1 -C 4 alkyl aryl, heteroaryl, C 1 -C 4 alkyl heteroaryl, carbonyl, or carbonylamino.
18. The method of claim 13 , wherein R 3 is aryl.
19. The method of claim 18 , wherein R 3 is substituted with heteroaryl, acyl, carboxyl, carbonylamino, nitro, amino, cyano, halogen, alkoxy, or hydroxyl.
20. The method of claim 18 , wherein R 3 is phenyl.
21. The method of claim 13 , wherein the compound is a pharmaceutically acceptable salt of:
22. The method of claim 13 , wherein the subject is administered a pharmaceutical composition comprising:
a) the effective amount of the compound; and
b) a pharmaceutically acceptable carrier.
23. The method of claim 22 , wherein the pharmaceutically acceptable carrier is a systemic or topical carrier.
24. The method of claim 23 , wherein the composition comprises about 0.001% to 10% of the compound and 90% to 99.999% of the systemic carrier.